Applied therapeutics inc. announces presentation of clinical data highlighting at-001 for the treatment of diabetic cardiomyopathy at the american heart association (aha) scientific sessions 2019

Applied therapeutics inc. announced the presentation of data at the american heart association (aha) scientific sessions 2019 in philadelphia (november 16-18, 2019) on at-001, a novel, potent and selective aldose reductase inhibitor (ari) in phase 3 clinical development for diabetic cardiomyopathy (dbcm). diabetic cardiomyopathy (dbcm) is a rapidly progressing degenerative disorder of the heart in patients with both type 1 and type 2 diabetes. there are no approved therapies for this fatal condition, which affects 17% – 24% of people with diabetes, or approximately 77 million patients worldwide. hyperglycemia, a symptom that characterizes diabetes, triggers the enzyme aldose reductase to convert excess glucose into sorbitol and fructose, both of which can lead to cell death in the heart muscle. when this happens, the heart fibroses, or “hardens,” such that the organ is unable to circulate blood through the body effectively. approximately 25% of patients with dbcm progress to overt heart failure or death within 1.5 years of diagnosis.
APLT Ratings Summary
APLT Quant Ranking